These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11166899)

  • 1. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.
    Goldstein G; Tribbick G; Manson K
    Vaccine; 2001 Feb; 19(13-14):1738-46. PubMed ID: 11166899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
    Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
    J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains.
    Tähtinen M; Ranki A; Valle SL; Ovod V; Krohn K
    Biomed Pharmacother; 1997; 51(10):480-7. PubMed ID: 9863510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
    Goldstein G; Chicca JJ
    Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
    Rodman TC; To SE; Hashish H; Manchester K
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length HIV-1 Tat protein necessary for a vaccine.
    Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
    Serrière J; Dugua JM; Bossus M; Verrier B; Haser R; Gouet P; Guillon C
    J Mol Biol; 2011 Jan; 405(1):33-42. PubMed ID: 21035463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.
    Ruckwardt TJ; Tikhonov I; Berg S; Hatfield GS; Chandra A; Chandra P; Gilliam B; Redfield RR; Gallo RC; Pauza CD
    J Virol; 2004 Dec; 78(23):13190-6. PubMed ID: 15542671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
    Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
    J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
    Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
    Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
    J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete mapping of a novel HLA A*6801-restricted HIV-1 Tat epitope directly with a rapid modified enzyme-linked immunospot assay.
    Oxenius A; Jakobsen BK; Easterbrook PJ; Boulter JM; Tun T; Waters A; Agudelo J; Barnardo M; Phillips RE; Price DA
    AIDS; 2002 Jun; 16(9):1285-7. PubMed ID: 12045495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
    Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
    J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of HIV1 gp120 3D B-cell epitopes mutability and variability: searching for possible vaccine epitopes.
    Khrustalev VV
    Immunol Invest; 2010; 39(6):551-69. PubMed ID: 20653424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.